BILLERICA, Mass., June 26, 2012 /PRNewswire/ -- Seahorse Bioscience, the world leader in manufacturing instrumentation and assay kits for measuring cellular metabolism, has announced the launch of its newest product, the XF Palmitate-BSA FAO Reagent, eliminating the need for radioactivity in fatty acid oxidation (FAO) assays.
The XF Palmitate-BSA FAO Reagent is a pre-conjugated, quality controlled fatty acid substrate in an aqueous solution that is readily absorbed and utilized by cells. Traditionally, FAO assays have been dependent on the Palmitate solubilizing, which is difficult to achieve and produces variable data.
"For researchers probing substrate utilization and fatty acid oxidation pathways, the process is no longer dependent on one's ability to prepare Palmitate. Each lot of the Seahorse XF Palmitate-BSA Reagent is functionally tested for activity in a fatty acid oxidation assay on the XF Analyzer, ensuring consistent performance; and the pre-conjugated, non-radioactive, ready-to-use solution eliminates any requirement of a lengthy conjugation protocol, so the assay is no longer intimidating to the researcher", stated Steve Chomicz, Seahorse Vice President of Sales, Marketing & Support.
For use with both the XF96 and XF24 Extracellular Flux Analyzers, the new XF Palmitate-BSA FAO Reagent introduces a standardized, ready-to-use, quality-controlled solution for measuring fatty acid oxidation providing true functional information, and consistent results in every assay, without radioactivity.
The XF Palmitate-BSA FAO Reagent will further advance the study of cellular bioenergetics, helping scientists to better understand the connection of physiological traits of cells with genomic and proteomic data. This knowledge will generate new insights into cellular bioenergetics and mitochondrial dysfunction, leading to a greater understanding, and new treatments of diseases as the human lifespan increases.
About Seahorse Bioscience
Seahorse Bioscience provides instrumentation and kits for cellular bioenergetic analysis for biological research and drug discovery applications. Over 1,500 scientists worldwide are advancing their research in understanding the role of metabolism in Neurodegeneration, Aging, Cancer, Cardiovascular, Toxicology, Immunology, Obesity, Diabetes, Metabolic Disorders, and Translational Medicine. Founded in 2001, Seahorse Bioscience is headquartered in Billerica, Massachusetts, U.S., and has regional offices in Copenhagen, Denmark; and Shanghai, China.
CONTACT: Naomi Goumillout, +1-978-671-1619, email@example.com
SOURCE Seahorse Bioscience, Inc.